Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — H1 2021 Earnings Presentation
17 slides from Hyphens Pharma International's earnings presentation, Aug 18, 2021
Slide 1: SGX Announcement: Results Briefing 1H2021
Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title GENERAL ANNOUNCEMENT::RESULTS BRIEFING 1H2021 General Announcement Date &Time of Broadcast 18-Aug-2021 12:3
Slide 2: Results Briefing 1H2021
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing 1H2021 18 AUGUST 2021
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 5: 1.1 Financial Performance
1.1 FINANCIAL PERFORMANCE Revenue (S$’m) Profit After Tax (S$’m) 65.4 4.2 63.4 61.6 62.1 3.5 3.4 56.0 3.1 1.0 * Excl JSS
Slide 6: 1.2 Income Statement
1.2 INCOME STATEMENT 1H2021 1H2020 YoY 2H2020 HoH 1H2021 vs 1H2020 S$'000 S$'000 % S$'000 % • Revenue increased across all business Revenue 65,376 61,640 6.1% 62,057 5.3% segments and most geographical locations. Cost of sales (40,624) (40,535) 0.2% (39,734) 2.2% Gross profit 24,752 21,105 17.3% 22,
Slide 7: 2.1 Revenue by Business Segments
2.1 REVENUE BY BUSINESS SEGMENTS 70.0 60.0 50.0 Revenue S$’mil 52% 56% 51% 53% 53% 40.0 30.0 13% 12% 15% 15% 15% 20.0 10.0 35% 32% 34% 32% 32% 0.0 1H2019 2H2019 1H2020 2H2020 1H2021 Specialty 29.5 35.7 31.4 33.2 34.8 Proprietary 7.1 7.4 9.2 9.1 9.4 Hypermart 19.4 20.3 21.0 19.8 21.2 Total 56.0 63.4
Slide 8: 2.2 EBITDA Margin by Business Segments
2.2 EBITDA MARGIN BY BUSINESS SEGMENTS 16.6% 13.1% 11.5% 9.5% 10.2% 8.5% 8.0% 7.4% 7.0% 5.5% 5.2% -0.2% Specialty pharma principals Proprietary brands Medical hypermart & digital FY2019 1H2020 2H2020 1H2021
Slide 9: Financial Position
3 FINANCIAL POSITION S$’000 30 Jun 2021 31 Dec 2020 Total assets 86,346 87,143 Inventories 15,086 16,888 Trade & other receivables 28,281 29,421 Cash & cash equivalents 30,921 27,526 Total liabilities 36,738 39,968 Trade & other payables 30,939 33,240 Bank borrowings 2,000 2,396 Total equity 49,608
Slide 10: Cashflow Statement
4 CASHFLOW STATEMENT S$'000 1H2021 1H2020 Cashflow from operating activities Profit before tax 5,230 5,149 Adjustments for non-cash/non-op items 1,056 871 Changes in working capital 1,003 (2,156) Tax paid (1,023) (223) Cashflow from operating activities 6,266 3,641 Cashflow used in investing activit
Slide 11: Business Updates
uu u w > Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 12: Reinforcing medical hypermart and digital segment
1 • Reinforcing medical hypermart and digital segment New talents who have joined us to lead new digital initiatives. Awarded e-pharmacy licence for WellAway Pharmacy.
Slide 13: New product launch
: pe NEW from Singap See Eye to Eye © with Hydration Promote Natural Tears, Help Relieve Dry Eyes HIGH STRENGTH 4 onikiy, ANTIOXIDANT CURCUMIN Natural nutrients that help with dry eyes “Best-selling fish oll (Omega-3) supplement in major retail pharmacies from 2013 to 2020. Avs. our regular Fish Oif
Slide 14: Strengthening specialty pharma portfolio
3 • Strengthening specialty pharma portfolio New Chemical Entity (NCE) THE MUCOLYTIC OF CHOICE FOR ALL RESPIRATORY DISORDERS Chronic WHAT IS A Respiratory Tract Obstructive Other Mucus- MUCOLYTIC? Infections Pulmonary Related Disorders A: Medicine that thins the Disease (COPD) mucus, making it easie
Slide 15: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 16: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma Portfolio 5. Acquisitions 6. Challenges – COVID-19
Slide 17: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — H1 2021 Earnings Presentation on 6ix